Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page shows a revision of enrollment/time-related fields: old status values such as Recruiting and Completed were removed, while new date fields with Actual/Estimated labels (including 2026-05-26, 2026-05-21, 2026-05, 2032-05) were added to reflect updated timelines.SummaryDifference4%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded Revision: v3.5.4 and removed ancillary items including Related Info, AbbVie, Helpful Links Provided by, and Revision: v3.5.3. These changes reflect a maintenance/update of the page rather than substantive updates to the study content.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site software update rather than a change to the study record itself.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page revision changed from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check87 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.